NUDT15 Antibody

Code CSB-PA885733LA01HU
Size US$166
Order now
Image
  • IHC image of CSB-PA885733LA01HU diluted at 1:300 and staining in paraffin-embedded human kidney tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

  • Immunofluorescent analysis of HepG2 cells using CSB-PA885733LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)

The Latest Promotion Free Antibody trial simple
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) NUDT15 Polyclonal antibody
Uniprot No.
Target Names
NUDT15
Alternative Names
8-dihydro-8-oxoguanine triphosphatase NUDT15 antibody; 8-oxo-dGTPase NUDT15 antibody; A730068G11Rik antibody; EC 3.1.6.- antibody; FLJ10956 antibody; MGC104352 antibody; MTH2 antibody; MutT homolog 2 antibody; Nucleoside diphosphate-linked moiety X motif 15 antibody; NUD15_HUMAN antibody; Nudix (nucleoside diphosphate linked moiety X)-type motif antibody; Nudix motif 15 antibody; NUDT15 antibody; OTTHUMP00000018389 antibody; Probable 7 antibody; Probable 7,8-dihydro-8-oxoguanine triphosphatase NUDT15 antibody; RP11-90M2.1 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Nucleotide triphosphate diphosphatase NUDT15 protein (1-164AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated

The NUDT15 Antibody (Product code: CSB-PA885733LA01HU) is Non-conjugated. For NUDT15 Antibody with conjugates, please check the following table.

Available Conjugates
Conjugate Product Code Product Name Application
HRP CSB-PA885733LB01HU NUDT15 Antibody, HRP conjugated ELISA
FITC CSB-PA885733LC01HU NUDT15 Antibody, FITC conjugated
Biotin CSB-PA885733LD01HU NUDT15 Antibody, Biotin conjugated ELISA
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA, IHC, IF
Recommended Dilution
Application Recommended Dilution
IHC 1:200-1:500
IF 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
May catalyze the hydrolysis of nucleoside triphosphates including dGTP, dTTP, dCTP, their oxidized forms like 8-oxo-dGTP and the prodrug thiopurine derivatives 6-thio-dGTP and 6-thio-GTP. Could also catalyze the hydrolysis of some nucleoside diphosphate derivatives. Hydrolyzes oxidized nucleosides triphosphates like 8-oxo-dGTP in vitro, but the specificity and efficiency towards these substrates are low. Therefore, the potential in vivo sanitizing role of this enzyme, that would consist in removing oxidatively damaged forms of nucleosides to prevent their incorporation into DNA, is unclear. Through the hydrolysis of thioguanosine triphosphates may participate in the catabolism of thiopurine drugs. May also have a role in DNA synthesis and cell cycle progression by stabilizing PCNA. Exhibits decapping activity towards dpCoA-capped RNAs in vitro.
Gene References into Functions
  1. Results show that 6-TGN levels were substantially low in patients with NUDT15 variants who showed highest hematopoietic toxicity. The low ratio of 6-TGN level to 6-mercaptopurine dose in patients with NUDT15 variants seems to be caused by enhanced incorporation of active thiopurine metabolites into DNA. PMID: 28903549
  2. Mutation rate of NUDT15 in Chinese inflammatory bowel disease patients is higher than that of TPMT. NUDT15 polymorphism is a better predictor for AZA-induced leukopenia than TPMT polymorphism. PMID: 29491687
  3. Mutations in exon 1 of NUDT15 also affect thiopurine-induced leukopenia in patients with inflammatory bowel disease. PMID: 29398872
  4. With increasing copy numbers of the risk T allele at NUDT15. PMID: 29210335
  5. results of this meta-analysis confirm that NUDT15 c.415C>T may be an important predictor of thiopurine-induced leukocytopenia in Asians PMID: 28470355
  6. NUDT15 c.415C>T, c.36_37insGGAGTC, and c.52G>A variants were risk factors for thiopurine-induced leukopenia. Combined detection of the 3 variants could increase the predictive sensitivity of thiopurine-induced leukopenia and help to distinguish early leukopenia in heterozygote of c.415C>T in Chinese patients with inflammatory bowel disease. PMID: 28570428
  7. Study replicated previous findings that the NUDT15 p.R139C variant is a potential predictor for AZA-induced leukopenia, extending this finding to patients with various neurological disorders in Korea and identifying its specific association with early leukopenia and severe alopecia. All of the patients who carried a NUDT15 p.R139C homozygous variant exhibited rapid development of severe leukopenia and extensive hair loss. PMID: 28566182
  8. Thiopurine treatment should not be recommended to patients with NUDT15 homozygous variant genotype due to severe early leukopenia PMID: 29206869
  9. All patients with both NUDT15 rs116855232 heterozygous variants and ABCC4 rs3765534 variants suffered from severe leukopenia and required 6-mercaptopurine dose reduction to less than 35 mg/m(2)/da PMID: 28883280
  10. Current review highlights the scientific data on NUDT15 enzyme variant in patients with acute lymphoblastic leukaemia and its relation to 6-mercaptopurine toxicity in various ethnic populations. PMID: 28963908
  11. 3 novel NUDT15 coding variants (p.R34T, p.K35E, and p.G17_V18del) in 5 children with acute lymphoblastic leukemia enrolled in frontline protocols in Singapore, Taiwan, and at St. Jude Children's Research Hospital. PMID: 28659275
  12. NUDT15 variant as a predictor for thiopurine-induced toxicity in Indian patients. PMID: 27416873
  13. NUDT15 gene polymorphism is related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. PMID: 26503813
  14. our results defined how NUDT15 limits thiopurine efficacy and how genetic ablation via the R139C missense mutation confers sensitivity to thiopurine treatment in patients PMID: 27530327
  15. NUDT15 polymorphisms are associated with 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia. PMID: 27577869
  16. NUDT15 c.415C>T may be another predictor of AZA-induced leukocytopenia. PMID: 27381176
  17. our study shows that 6-MP reduction is significant in the younger age group in relation to NUDT15 variant PMID: 27193222
  18. NUDT R139C T/T genotype showed complete association with early severe hair loss/leukopenia in Japanese patients with inflammatory bowel diseases. PMID: 26076924
  19. Letter: discuss role of NUDT15 in complex thiopurine metabolism. PMID: 27308664
  20. There was a close association of NUDT15 R139C with early leukopenia associated with thiopurines in patients in Hong Kong PMID: 27095468
  21. These results suggest that NUDT15 R139C-related thiopurine-induced leukocytopenia is mediated by a 6-TGN-independent mechanism. PMID: 26590936
  22. Mutations of the NUDT15 and TPMT gene accounted for approximately 88% of cases with thiopurine-induced early leukopenia. Extensive hair loss was a recognizable early symptom in patients with the homozygous NUDT15 c.415C>T variant. PMID: 26735160
  23. NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. PMID: 26405151
  24. Patients with defective NUDT15 alleles showed excessive levels of thiopurine active metabolites and toxicity. [meta-analysis] PMID: 26878724
  25. Depletion of NUDT15 has no effect on incorporation of 8-oxo-dGTP into DNA and does not impact cancer cell survival in cell lines tested. NUDT15 is not a biologically relevant 8-oxo-dGTPase PMID: 26238318
  26. Event-free survival did not significantly differ by NUDT15 genotype. rs116855232 is an important determinant of 6-MP myelotoxicity in Japanese children with ALL and may represent the most robust toxicity-related locus in Asians to date. PMID: 26033531
  27. Describe a germline variant in NUDT15 strongly associated with mercaptopurine intolerance in childhood acute lymphoblastic leukemia, which may have implications for treatment individualization in this disease. PMID: 25624441
  28. Authros identified a nonsynonymous SNP in NUDT15 (encoding p.Arg139Cys) that was strongly associated with thiopurine-induced early leukopenia (odds ratio (OR) = 35.6; P(combined) = 4.88 x 10(-94)). PMID: 25108385
  29. human MTH1, MTH2, and NUDT5 proteins act as a defense against the mutagenesis induced by oxidized dGTP. PMID: 20144704
  30. Data demonstrate for the first time that PCNA is protected by this newly identified partner molecule MTH2, which is related to DNA synthesis and cell cycle progression. PMID: 19419956

Show More

Hide All

Protein Families
Nudix hydrolase family
Database Links

HGNC: 23063

OMIM: 615792

KEGG: hsa:55270

STRING: 9606.ENSP00000258662

UniGene: Hs.144407

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*